http://www.guardian.co.uk/education/...oct/15/physics

More potentially good news for sufferers of Parkinson's disease. After yesterday's announcement of successful studies for Phytopharm's Cogane treatment, comes a positive update from Oxford BioMedica.

The gene therapy company said new Phase 2 data showed patients showed improvement after receiving a second dose of its ProSavin treatment. The company said after this six month assessment there was now the opportunity to try a higher dose which could be even more effective. Meanwhile a research paper on ProSavin published yesterday in the Science Translational Medicine journal also suggested positive results from the treatment.

Much like Phytopharm yesterday, the news has lifted Oxford's shares and they are now 9p higher at 19.75p. KBC Peel Hunt issued a buy note with a 17p price target (since overtaken by the market's enthusiasm)
Parkinson's disease is notorious for having patients that have spontaneous and non-treatment related bounce, which may in fact have been caused by better standard of care having the patients looked at in hospital by some of the world's greatest neurologists.

Imad

Observations on both of these are best viewed in context of each other.

Debi